inner-banner

STARRT-AKI

ANZICS CTG Endorsed Study

STARRT-AKI

Standard versus accelerated initiation of renal replacement therapy in acute kidney injury

Study Description

To determine whether immediate initiation of renal replacement therapy (RRT), compared to delayed approach to RRT initiation, improves survival and renal recovery (RRT independence) at 90 days in critically ill patients with severe AKI.

Management Committee

Martin Gallagher (Chair), Sean Bagshaw, Rinaldo Bellomo, Heidi Buhr, Raulle Sol Cruz (PM NZ), Erika Dempsey (Project Manager), Glenn Eastwood, David Gattas, Shay McGuinness, Rachael Parke, Andrew Udy, Ron Wald , and Amanda Wang.

Project Managers

Erika Dempsey (Australia)
Raulle Sol Cruz (New Zealand)

Administering Institution

The George Institute for Global Health, Australia (Renal and Metabolic Division)
Medical Research Institute of New Zealand

Collaborators

St Michael’s Hospital, Canadian Critical Care Trials Group
Medical Research Institute of New Zealand

Sample Size

2866 patients

Funding

St Michael’s Hospital (Start-up funds per contractual agreement) CAN$120,000
NHMRC $2.1 million
HRC (NZ) $1.19 million

Project Status as of June 2018

STARRT-AKI is recruiting well, both globally and in the ANZ region. Globally, the study has recruited 1847 patients out of a target of 2866 (64%). In the ANZ region, we’ve recruited 317 patients out of a target of 700 (45%). There are 125 sites from 12 countries recruiting globally, with 21 sites from ANZ.

Sites in ANZ are recruiting as expected at a rate of approximately 0.9 patients per site per month. In February 2018, our international study leads from Canada hosted a Webinar to provide a study update, to discuss study recruitment barriers, and to provide a forum for questions and discussion.

A DSMB meeting was held in January 2018, reviewing data for the first 900 patients, and it was communicated that the study should continue with no major concerns raised.

Contact

Rinaldo Bellomo (email)
Erika Dempsey (email)

Reference

CTG1516-02
NCT02568722